# Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors

> **NCT07558200** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 138 (estimated)

## Conditions studied

- Solid Tumors
- Non-Small Cell Lung Cancer
- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Intervention1：FXB0871
- **BIOLOGICAL:** Intervention2：FXB0871
- **BIOLOGICAL:** Intervention3：FXB0871
- **BIOLOGICAL:** Intervention4：FXB0871

## Key facts

- **NCT ID:** NCT07558200
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2030-04-23
- **Final completion:** 2030-11-18
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07558200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07558200, "Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07558200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*